Health
Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin
ZUG, Switzerland, June 25, 2025--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of nemolizumab in treating patients living with Systemic Sclerosis (SSc) and Chronic Pruritus of Unknown Origin (CPUO) – two chronic conditions with high unmet need.1-3,7
About this update from Galderma Group Ag
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":823,"height":209,"url":"https://media.zenfs.com/en/business-wire.com/7a9f8431d66eb6b2b9d8370972bb141e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fv9kjN533VWOgJAla6K7KQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI0NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/7a9f8431d66eb6b2b9d8370972bb141e","width":823,"height":209},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/pYngeanbErNi5N9v0aExuQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE2NDY7aD00MTg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/7a9f8431d66eb6b2b9d8370972bb141e","width":823,"height":209}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Systemic Sclerosis (SSc) is a life-threatening autoimmune disease that causes severe inflammation and fibrosis, while Chronic Pruritus of Unknown Origin (CPUO) is characterized by a persistent, chronic itch with an unknown cause1-3","length":231,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Nemolizumab is the first approved monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31. It is approved for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world4-6","length":290,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"IL-31 is a neuroimmune cytokine that is involved in inflammation and fibrosis – both hallmarks of SSc – and drives itch, a key symptom of CPUO1,3,4","length":147,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Enrollment for Galderma’s phase II studies of nemolizumab is planned to begin in H2 2025","length":88,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":756,"olType":false},{"type":"text","content":"ZUG, Switzerland, June 25, 2025--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of nemolizumab in treating patients living with Systemic Sclerosis (SSc) and Chronic Pruritus of Unknown Origin (CPUO) – two chronic conditions with high unmet need.1-3,7","length":382,"tagName":"p"},{"type":"text","content":"Nemolizumab is a monoclonal an...